Innovating Works

ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE

Activa
Mostrando 1 al 20 de 257 resultados
MagFetProg: Magnesium and fetal metabolic programming: an approach to preventing a life-cycle of metabolic diseases ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE tramitó un HORIZON EUROPE: Obesity prevalence is increasing as well as the related metabolic alterations. Obesity and T2D increase the risk of pregnancy complication and affect offspring health through developmental programming...
2024-04-23 | Financiado
SPIRAL: Structural exploration of GD3 ganglioside-COVID spike Protein Interaction and siglec-7 Role in inhibition of virAL infection ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE tramitó un HORIZON EUROPE: The present project focuses on deeply comprehending the molecular basis of glycan recognition events by key protein receptors at atomic level, directly connected to processes related to immune respons...
2024-04-10 | Financiado
EPIMemory: Epithelial Memory to Candida albicans during commensalism and infection ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE tramitó un HORIZON EUROPE: In this research project I seek to discover the mechanisms underlying oral epithelial cell (OEC) memory and its importance to control Candida albicans infections and commensalism. C. albicans is part...
2024-03-22 | Financiado
ADJUPROBE: LEAD ADJUVANT PROBE AS A DUAL TECHNOLOGICAL TOOL TO ADVANCE NEXT-GENERATION VACCINE DEVELOPMENT ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE tramitó un HORIZON EUROPE: The goal of ADJUPROBE is to build upon a major discovery made within the ERC-2016-STG-716878 project to validate and valorise our dual synthetic technological tool, moving it forward to boost vaccine...
2023-11-15 | Financiado
Glyco13Cell: Isotopically labelling of cell surface glycans to illuminate infectious processes at atomic resolution ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE tramitó un HORIZON EUROPE: Every human cell is covered by a dense coat of glycans (sugars, carbohydrates). Sugars are the first molecules that viruses encounter when they approach host cells. Many viruses encode lectins to adhe...
2023-11-14 | Financiado
ADJU-PLATFORM: MINIMAL SAPONIN-BASED ADJUVANT VACCINE PLATFORM ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE tramitó un HORIZON EUROPE: ADJU-PLATFORM seeks to leverage a breakthrough made in the ERC-2016-STG-716878 project to validate a synthetic technological platform for the efficient production of optimised saponin adjuvants and im...
2023-03-09 | Financiado
EVCA: Centre for Excellence in Diagnostic and Advanced Therapeutics based on Extracellular Vesicles UNIVERSIDADE NOVA DE LISBOA tramitó un HORIZON EUROPE: In recent years, extracellular vesicles (EVs) have emerged within the scientific community for both biomarkers and therapeutic applications. However, the translation of the research findings represent...
2022-09-09 | Financiado
ADJUVACCINE: Development of a marketable adjuvant candidate for vaccine applications ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE tramitó un HORIZON EUROPE: ADJUVACCINE seeks to leverage a breakthrough made in the ERC-2016-STG-716878 project to validate a synthetic technological platform for the scalable production of identified optimised saponin adjuvant...
2022-07-08 | Financiado
FIH-IO: Development of a first-in-class inhibitor of FIH for cancer immunotherapy ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE tramitó un HORIZON EUROPE: We plan to carry out a valorisation project for a series of novel small molecule inhibitors of Factor Inhibiting HIF (FIH) that we have developed for the treatment of lung cancer, as a next-generation...
2022-05-12 | Financiado
PDC2022-133677-I00: USO TERAPEUTICO DE CICLOPIROX EN PORFIRIA CUTANEA TARDA ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE tramitó un AEI: LA PORFIRIA CUTANEA TARDS (PCT) ES LA FORMA MAS FRECUENTE DE PORFIRIA Y RESULTA DE MUTACIONES DELETEREAS POR SUSTITUCION EN EL GEN UROD. PCT AFECTA PRINCIPALMENTE A LA PIEL Y ACTUALMENTE NO EXISTE UN...
2022-01-01 | Financiado
PDC2022-133537-I00: VALORIZACION DE AGENTES TERAPEUTICOS DIRIGIDOS A RECEPTORES DE GLICANOS DEL CONTROL INMUNITARIO ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE tramitó un AEI: SIGLEC-9 OFRECE OPORTUNIDADES TERAPEUTICAS QUE SE DIFERENCIAN Y COMPLEMENTAN CON EL BLOQUEO CLASICO DEL RECEPTOR DEL PUNTO DE CONTROL (ES DECIR, PD-1), CON EL POTENCIAL DE DESARROLLAR UNA NUEVA CLASE...
2022-01-01 | Financiado
PDC2022-133300-I00: VALORIZACION DE PEQUEÑAS MOLECULAS INHIBIDORAS DEL FACTOR INHIBIDOR DE HIF (FIH) PARA EL TRATAMIENTO DEL CANCER DE PULMON ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE tramitó un AEI: EL OBJETIVO PRINCIPAL DE ESTA PROPUESTA ES CONTINUAR EL DESARROLLO DE SERIES DE COMPUESTOS QUIMICOS PEQUEÑAS MOLECULAS INHIBIDORAS DE FIH (ACTIVIDADES HIT-TO-LEAD) A TRAVES DE LA ITERACION ENTRE ACTIV...
2022-01-01 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.